Introduction
For many years gene therapy researchers have striven to develop a cure for haemophilia A. This bleeding disorder is an X-linked recessive disease resulting from a deficiency in factor VIII (FVIII) that affects 1 in 5000 to 10 000 males. Haemophilia is currently treated by intravenous injection of clotting factor concentrates. The use of prophylactic protein replacement therapy reduces the risk of severe haemorrhage and chronic joint damage but necessitates frequent venous access and increased consumption of FVIII. Furthermore, despite improved screening and treatment of human plasma, transmission of infectious agents from contaminated blood sources is still a concern. This has been alleviated by the introduction of recombinant FVIII, however, in many parts of the world FVIII products are prohibitively expensive and standards of treatment remain inadequate.
Gene therapy could address these issues by providing a constant supply of endogenously synthesized clotting factor. Normal human plasma contains 100-200 ng ml À1 FVIII; however, the therapeutic window is wide and levels as low as 2% of this provide clinical benefit. The development of gene transfer systems for treating haemophilia A have been hindered by the low expression of FVIII which is two orders of magnitude lower than for other proteins. 1 This is ascribed to the presence of transcriptional silencers within the FVIII cDNA [2] [3] [4] and inefficient intracellular transport and secretion of the protein. 5 The construction of retroviral vectors encoding FVIII has been especially problematic and is attributed to inefficient transcription of the vector genome. Such vectors frequently displayed rearrangements or deletions suggesting selection against the presence of an intact FVIII gene in retroviral producer cells. 6, 7 The generation of vectors with improved titres appears to be related to the presence of an intron 7, 8 which is postulated to counteract transcriptional repression leading to increased mRNA accumulation. 9 Sustained levels of FVIII were not detected in patients administered with a retroviral construct 10 and therefore more recently studies have focused on the use of lentiviral vectors which are capable of transducing a wide variety of terminally differentiated cell types including hepatocytes. 11 Long-term expression of B domain-deleted (BDD) FVIII in murine models has been reported using both human immunodeficiency virus-1 (HIV-1)- [12] [13] [14] and feline immunodeficiency virus (FIV)-based 15 ,16 lentiviral vectors; however, plasma levels of FVIII have generally been low. Whilst evaluating equine infectious anaemia virus (EIAV)-based lentiviral vectors for the delivery of BDD FVIII we observed these vectors had titres at least two orders of magnitude lower than equivalent vectors encoding reporter genes such as bgalactosidase. This was found to be primarily due to expression of the FVIII gene in producer cells: coexpression of FVIII is an inhibitor of functional vector production. It was necessary to carry out an assay for transduction-competent particles in order to detect this. A surrogate titre assay, for performance enhanced reverse transcriptase (PERT) activity, did not detect any effect on viral particle production and real-time PCR measurement of viral RNA genome levels greatly overestimated titre.
Further investigation into the mechanism by which FVIII inhibits viral production revealed that the levels of vesicular stomatitis virus G (VSV-G) envelope on viral particles derived from cells co-expressing FVIII are greatly reduced. Resultant viral vector is thus unable to enter target cells due to inefficient pseudotyping of particles. This was observed to varying degrees with a range of different envelopes and also HIV-1 and MLV vector systems. In order to circumvent this we sought to prevent expression of the vector transgene in producer cells. This was achieved by replacing the promiscuous human cytomegalovirus (CMV) immediate early enhancer/promoter with a liver-specific promoter, which is less active in HEK293T producer cells. By replacing the internal promoter the titre of vectors encoding the BDD FVIII gene were considerably increased. The results of this study underscore the importance of obtaining functional (that is, transducing), rather than deduced, titres for therapeutic vectors.
In an attempt to increase FVIII expression per vector copy with the aim of minimizing the efficacious clinical dose, a highly desirable goal from both safety and manufacturing perspectives, we decided to re-engineer the codons of the BDD and full-length FVIII genes. The translational efficiency of the FVIII mRNA was previously found to be comparable to that of two other mRNAs tested, that is, vWF and dihydrofolate reductase;
1 therefore, it was anticipated that any enhancement of gene expression would likely be modest. Here we report that, whereas the impact of codon-optimizing the BDD FVIII gene was indeed modest, codon optimization of the fulllength FVIII gene improved vector titres approximately one order of magnitude and also greatly increased expression per vector copy as compared to vectors encoding the equivalent wild-type FVIII sequence.
Results

Codon optimization of the human BDD FVIII gene
The human BDD FVIII nucleotide sequence was codonoptimized according to the codon usage of highly expressed human genes 17 as shown in Table 1 . Prior to synthesis (Cytomyx, Cambridge, UK) the sequence was analyzed to ensure no undesirable elements, such as splice sites, were present. The GenBank accession number for this sequence is EU159410.
Analysis of EIAV vectors expressing FVIII
The wild-type and codon-optimized BDD FVIII genes were cloned into a minimal EIAV vector downstream of the CMV immediate early enhancer/promoter (Figure 1 ). Viral vector was produced by three-plasmid transient co-transfection and titered using the following three assays:
(i) PERT assay, which estimates particle numbers based on reverse transcriptase activity. (ii) RNA assay, which measures vector genome copies by real-time PCR. (iii) Integration assay, which measures proviral vector copies following transduction of HEK293T cells.
Data from these assays ( Figure 2 ) indicated that particle numbers, as measured by the PERT assay, for the FVIII viral vectors (pONY8.7NCFco and The PERT predicted titres of these vectors when normalized to an EIAV reference standard were approximately 2 Â 10 6 transducing units (TU) per millilitre. The levels of RNA genome, however, for the codon-optimized and wild-type FVIII vectors were 10-and 100-fold lower respectively than obtained for the b-galactosidase vector. Therefore, the predicted titres from these two assays are not in agreement. As mRNAs encoding FVIII are reported to accumulate to only low levels it is possible that reduced quantities of genomic RNA transcripts are available for packaging. This would result in an increased proportion of empty viral particles explaining the observed discrepancy. An integration assay to measure proviral vector copies in transduced cells was performed. This revealed that the functional titres of the FVIII vectors, as measured by integrated copies of proviral vector DNA, were so low that they fell below the accurate quantitation limits of the qPCR assay (this is dictated by the copy number standard curve and corresponding Ct values). These data show that predicted titres based on quantitation of RNA genome levels and PERT activity are overestimating actual titre by at least two and three orders of magnitude respectively.
Expression of FVIII inhibits functional viral production
In order to further investigate the low titres obtained with vectors encoding FVIII we devised a number of experiments to dissect the cause(s) and in particular whether the inhibitory mechanism operates in cis or trans. We conducted a genome mixing experiment to determine whether the presence of a FVIII genome had a dominant inhibitory effect on the titre of a heterologous vector genome encoding the reporter gene b-galactosidase (pONY8.7NCZ). Equal quantities of the two genomes were used to prepare viral vector by transient transfection. As a control we also prepared vector with equal quantities of GFP and b-galactosidase marker genomes. Vector was titered by serial dilution on D17 cells that were X-gal stained to score b-galactosidase expressing cells.
The results of this experiment ( Figure 3 ) showed that the FVIII genome (pONY8.7NCFco) was indeed having a dominant inhibitory effect on the production of a vector encoding a marker gene: titres were over two orders of magnitude lower than those obtained when the GFP control genome (pONY8.7NCG) was co-transfected. Therefore, either the FVIII genome itself, or the gene product, has a detrimental effect on viral production. As vectors encoding both wild-type and codon-optimized FVIII genes have low titres it is unlikely that the nucleic acid sequence of the genome is a factor. In agreement with this co-transfection of a mammalian expression vector (pCI-neo, Promega, Madison, WI, USA) encoding FVIII (pFVIII, Figure 1 ) was found to inhibit vector production by three orders of magnitude compared to the pCI-neo control ( Figure 3 ). These data indicate that Lentiviral vectors for factor VIII gene transfer PA Radcliffe et al expression of FVIII in HEK293T producer cells inhibits the production of functional vector. To confirm that the presence of the FVIII coding sequence within a vector genome has no deleterious effect on titre per se the internal CMV promoter was removed from the pO-NY8.7NCFco genome to give pONY8.7NFco (Figure 1 ). Vector prepared with this genome is able to efficiently transduce target cells as measured by integration assay (Figure 4) . We therefore concluded that expression of FVIII is a potent inhibitor of EIAV vector production.
FVIII expression abrogates efficient pseudotyping of viral particles
To test which component(s) of the viral particle is affected by FVIII expression we analyzed viral supernatants by western blotting. Although reverse transcriptase activity is unaffected (Figure 2) , it is possible that the function or processing of some other Gag/Pol protein is being inhibited. Another possibility is that the VSV-G envelope is affected. We observed that virus produced in HEK293T cells co-expressing FVIII had comparable or modestly reduced levels of Gag/Pol with no obvious defect in processing apparent from the relative amounts of protein detected (Figure 5a ). The most dramatic effect on viral particles is on the quantity of VSV-G envelope detected (Figure 5b ). Taken together, the analysis of vector particles produced in cells co-expressing FVIII shows that viral particles are produced at normal levels and that genome is efficiently packaged, however, the particles have insufficient envelope to facilitate efficient entry into target cells.
Inhibition of pseudotyping by FVIII is not specific to EIAV or VSV-G
In order to investigate whether this effect is peculiar to EIAV vectors and/or VSV-G, co-transfection experiments were conducted to test the effect of FVIII expression on the titre of both HIV-1 and murine leukaemia virus (MLV) vectors as well as on EIAV vectors pseudotyped with a variety of different envelope glycoproteins including those from Ross River Virus (RRV), Lymphocytic Choriomeningitis Virus (LCMV), Ebola, amphotropic MLV (ampho), rabies and an alternative VSV-G isoform (pHCMV-G). The titres of HIV-1 and MLV vectors were reduced by approximately 5-and 10-fold respectively (Figure 6a ). Similarly the titres of EIAV vectors pseudotyped with alternative envelopes were all adversely affected (Figure 6b ). FVIII expression therefore appears to have a detrimental effect on the normal processing of viral envelope glycoproteins resulting in a negative impact on titre. This effect is particularly pronounced in the case of the minimal EIAV vector system when vectors are pseudotyped with VSV-G expressed from pRV67 and may be related to the low quantity of envelope plasmid used. Indeed the effect on titres of EIAV prepared using increased quantities of pRV67 was comparable to that observed for the HIV-1 vector (data not shown). Interestingly the alternative VSV-G envelope (pHCMV-G) appears to be less sensitive to the effects of FVIII expression even when low quantities are used.
Incorporation of a tissue-specific promoter restores viral titre
To address the issue of poor vector titres we sought to prevent the expression of FVIII in producer cells. As removal of the internal CMV promoter was able to circumvent the inhibition of vector production ( Figure 4) we constructed vector genomes incorporating tissuespecific promoters such as pONY8.95NAF (Figure 1 ) in which FVIII expression is under the control of the human a 1 -antitrypsin (hAAT) liver-specific promoter. Levels of FVIII in samples of tissue culture supernatant taken from producer cells 24 h post transfection were approximately fivefold lower for vector prepared using the pONY8.95-NAFco genome compared to the original vector containing an internal CMV promoter. This difference was less Figure 4 The presence of a FVIII coding sequence within a vector genome does not per se affect titre. Removal of the internal promoter from pONY8.7NCFco (pONY8.7NFco) restores functional titre, to levels comparable to a control (pONY8.7NCZ), as measured by the DNA titre assay for integrated copies. Hatching indicates a titre below the accurate quantitation limits of the assay. 
than expected from a previous study in which the activity of the two promoters was compared in HEK293 cells (a greater than 100-fold difference was reported) 18 and may be due to interference caused by the presence of a strong enhancer/promoter in the 5 0 long-terminal repeat. In addition to vectors encoding the BDD FVIII genes, we also constructed vectors encoding wild-type and codon-optimized (Geneart, Regensburg, Germany. GenBank accession number EU159409) full-length FVIII. We prepared vector using the new FVIII genomes alongside a control genome encoding b-galactosidase (pONY8.95NAZ) and analyzed titre by integration assay. The data shown are for vectors pseudotyped with the alternative VSV-G isoform and confirm that production of high titre EIAV vector for the delivery of FVIII could be achieved using an internal liver-specific promoter (Figure 7a ). Similar results were obtained for vectors pseudotyped with VSV-G expressed from pRV76 (data not shown). Furthermore, we observed that codon optimization of the full-length FVIII gene confers an improvement in functional (DNA) titre of approximately 10-fold compared to vector encoding the equivalent wild-type FVIII sequence. This difference in functional titre is not reflected in the levels of genomic RNA, which are only modestly enhanced by codon optimization. These data suggest that compromised transcriptional efficiency, or mRNA stability, leading to a decrease in the amount of genome available for packaging may be a factor in the low titres obtained for vector encoding the full-length wild-type FVIII cDNA but does not fully account for the observed discrepancy.
Codon-optimization improves FVIII protein production
To determine whether codon optimization of FVIII results in enhanced protein expression, vectors encoding the codon-engineered BDD and full-length genes and the wild-type equivalents were prepared and concentrated by centrifugation. FVIII levels in the culture media of transduced HepG2 cells were analyzed by COATEST (Figure 7b ). Cells transduced with the vectors encoding the codon-engineered BDD gene secrete approximately threefold more FVIII protein per vector copy than those containing the unaltered sequence. Cells transduced with vector encoding the codon-optimized full-length FVIII secrete levels comparable to those encoding the wild-type BDD FVIII. It was not possible to quantify the FVIII secreted by cells containing wild-type full-length FVIII as levels were below the limits of detection of the assay. Comparable samples from cells transduced with vector encoding the codon-optimized full-length FVIII are calculated to contain in excess of 100-fold more FVIII than the Lentiviral vectors for factor VIII gene transfer PA Radcliffe et al lowest standard, therefore, codon optimization of the fulllength FVIII cDNA has improved expression per copy by at least two orders of magnitude. As the hAAT promoter used to drive expression of the transgene is the minimal (305 bp) region 18 it may be possible to increase the absolute quantity of FVIII produced per copy still further by using a modified, or alternative, promoter.
Discussion
We report the development of an optimized lentiviral vector system for the treatment of haemophilia A. The vectors described here are minimal non-primate lentiviral vectors which are produced in the absence of all viral accessory genes. 19 Analysis of vectors encoding FVIII revealed that expression of FVIII protein in producer cells inhibits viral pseudotyping. This discovery could account, in part, for some of the findings of previous studies, which reported difficulties in producing high titre retroviral gene therapy vectors for FVIII gene transfer. Such studies have generally utilized functional assays, for example G418 resistance, for determining titre. We note that it is common practice to titre HIV-1 vectors containing therapeutic genes by p24 Gag antigen ELISA and normalizing to a vector encoding a marker gene manufactured in parallel. Our data show that this is an unsatisfactory method of predicting titre, even where the therapeutic gene is well characterized. It is therefore possible that some in vivo studies have had somewhat disappointing results as the actual dose used may be considerably lower than realized. Our results are in general agreement with a previous report in which titres of a bicistronic HIV-1 vector expressing FVIII and EGFP were found to be 10-fold lower than a vector expressing EGFP alone. 20 Our analysis indicates that the impact of FVIII expression on viral pseudotyping is a general one; in our hands all vector systems and viral glycoproteins tested were affected. The minimal EIAV vector system may be unusually sensitive due to the low quantity of VSV-G envelope plasmid used in the optimized production system. Furthermore, the VSV-G envelope used was more severely affected than any other envelope tested including a more commonly used VSV-G isoform differing by single amino-acid residue (threonine rather than alanine at position 336) known to be involved in glycosylation. 21 These factors resulted in a catastrophic drop in titre, whereas for other vector system/envelope combinations a less obvious decrease would only be unmasked by thorough characterization of vector and may explain why this phenomenon has thus far gone unnoticed. The precise mechanism of the inhibitory effect remains to be elucidated: FVIII has been shown to colocalize with VSV-G throughout its secretion 22 and we speculate that high-level expression of FVIII may overwhelm the secretory machinery blocking normal trafficking of the envelope glycoprotein.
It is difficult to compare the absolute FVIII expression per vector copy observed in this study with that achieved in other vector studies due to differences in cell types transduced and promoters. In a previous study in which expression was also analyzed in transduced HepG2 cells, the reported FVIII production using a retroviral vector containing a 5 0 intron was 1 ng 10 À6 cells per 24 h. 7 Assuming transduced cells contained a single vector copy, this is similar (within twofold) to the levels observed in this study for the wild-type BDD FVIII despite the different vector backbones/promoters used. In another study in which expression of FVIII was directed from an internal hAAT promoter in the context of an HIV-1-based lentiviral vector, also containing the WPRE, FVIII levels of 27 ng 10 À6 cells per 24 h were reported.
14 As the number of vector copies per cell was not given, and as the cell type (Huh7) and promoter (an additional 100 bp of 5 0 sequence present) were different, it is not possible to compare these data directly; however, this value is within the range we observed at higher multiplicities of infection (data not shown). The FVIII expression levels reported by Dwarki et al. 8 using the MFG retroviral vector system, and also Kootstra et al. 13 who used an HIV-1 vector containing an internal CAG promoter, were considerably more (at least two orders of magnitude) than we observed. It is not clear why such high-level FVIII production was achieved using these two vectors in comparison to most other reports; in both cases robust promoters were used, a 5 0 intron was present and, unlike some retroviral vectors, they did not contain a selectable marker.
Substitution of the wild-type BDD FVIII gene with a codon-engineered sequence yielded only modest improvements in titre and expression (approximately two-and threefold respectively) in line with a previous study in which conserved mutagenesis of a putative 1.2 kb FVIII RNA inhibitory sequence failed to yield an increase in titre. 7 However, codon engineering of the fulllength FVIII led to a substantial increase in titre of approximately 10-fold. We speculate that the increase in titre obtained with our codon-optimized gene is as a result of the serendipitous elimination of multiple transcriptional silencers within the B domain; such elements are thought to be widely distributed throughout the FVIII cDNA. 2, 3, 6 The most dramatic impact of codon optimizing the cDNA is on expression of the FVIII gene which we have been unable to quantify due to the low level of FVIII expressed from the native cDNA but is calculated to be enhanced at least 100-fold.
In the majority of recent preclinical studies in which the liver is the target organ a tissue-specific promoter, such as the a 1 -antitrypsin promoter, has been used to direct expression of FVIII. Although the CMV promoter directs high-level expression in hepatocytes in vitro 23 it has been reported to shut down in the liver. 24 It has been proposed that this may be due to transduction and subsequent expression in antigen presenting cells triggering immune-mediated destruction of transduced hepatocytes and the transgene product. 25 Restricting expression to the liver by using a tissue-specific promoter appears to alleviate this in some, 25 although not all, 14 cases. As silencing of the CMV promoter occurs following ex vivo transduction of hepatocytes, 26 it is likely that multiple factors are at play. In any case the selection of a ubiquitous promoter for directing expression of FVIII is now less favoured. Consequently most vectors contain tissue-specific promoters as standard and the likelihood of decreased titres, as a result of inefficient pseudotyping, is much reduced. Nevertheless, our experience emphasizes the importance of conducting comprehensive analyses of vectors, including functional titre assays, for all vector genomes. This study suggests the vector encoding the codonoptimized BDD FVIII is optimal in terms of titre and expression and therefore this would be the vector of choice for performing an efficacy study. However, we report that codon optimization of the full-length FVIII had a dramatic impact resulting in vector titres comparable to those obtained with vector encoding the commonly used wild-type BDD sequence and yielding equivalent expression per copy. The use of a lentiviral vector encoding native FVIII protein is therefore a feasible therapeutic option. Furthermore, other gene delivery and FVIII production systems which preferentially utilize the full-length gene would benefit from the enhanced expression profile of the codon-engineered version. The optimized EIAV vectors described here are currently being evaluated in vivo.
Materials and methods
Cell lines
HEK293T cells were obtained from M Calos (Stanford University) and maintained in Dulbecco's modified Eagle's medium containing 10% (v/v) foetal calf serum (FCS) supplemented with 2 mM L-Glutamine and 1% non-essential amino acids (NEAA) as were D17 (canine osteosarcoma) cells. HepG2 cells were maintained in EMEM containing 10% (v/v) FCS supplemented with 2 mM L-Glutamine, 1 mM sodium pyruvate, 0.15% sodium bicarbonate and 1% NEAA.
Transient plasmid expression system and vector titration
Transient vector production was carried out by three plasmid co-transfections of HEK293T cells using FuGENE6 (Roche, Mannheim, Germany) as previously described 27 except that media was changed 6-8 h after sodium butyrate addition and vector collected for analysis 42 h post transfection. Vectors were not concentrated unless otherwise stated. The following quantities of plasmid were used per 10 cm dish: 4 mg genome plasmid, 2 mg EIAV synthetic Gag/Pol (pESYNGP) 28 and 0.08 mg VSV-G envelope plasmid (pRV67 29 unless otherwise stated). Concentrated vectors were prepared using 440 mg genome plasmid, 220 mg EIAV synthetic Gag/Pol (pESYNGP) 28 and 8.8 mg VSV-G (phG[VSVG2]) 21 envelope per 10-layer cell factory. Vector containing marker genes was titred by serial dilution on D17 cells as previously described; 27 transduction with vectors encoding EGFP was assessed by flow cytometry and those encoding lacZ by X-gal staining and visual scoring of colonies.
Genome mixing experiments
Vector was prepared transiently as described above except that the 4 mg of genome plasmid comprised 2 mg each of reporter and test genome (or plasmid). The following quantities of envelope plasmids were used, that is, 0.08 mg pRV67 (VSV-G); 0.08 mg pHCMV-G (VSV-G); 30 1.1 mg pM108 (LCMV); 27 0.032 mg pVRC6002 (Dmuc Ebola Zaire); 31 2 mg pHIT456 (MLV amphotropic envelope); 29 2 mg pRRV (Ross River virus) a kind gift from D Sanders; 32 0.3 mg rabies CVS. 27 HIV-1 vectors were prepared as previously described 33 using 2 mg of pSYNGP, 1 mg pRV67 and 2 mg each of pH7GW and test plasmid. pH7GW contains the WPRE 3 0 of EGFP and is derived from pH7G which was constructed from pH6NZ 33 by exchanging the LacZ reporter gene for EGFP and inserting the cPTT/CTS 5 0 of the internal CMV promoter. MLV vectors were prepared as previously described 29 using 2 mg of pHIT60, 2 mg each of pHIT111 and test plasmid and either 1 mg of pRV67 or 2 mg of pHIT456.
Performance enhanced reverse transcriptase assay (PERT)
Analysis of vector samples by PERT assay was conducted as previously described 28 except that vector particles were disrupted prior to dilution and One-step RT-PCR Master Mix containing Reverse Transcriptase and RNaseI Inhibitor (Applied Biosystems, Roche, Branchburg, NJ, USA) was used to prepare reaction mixes.
Integration (DNA) titre assay HEK293T cells were transduced and passaged (1 in 5) three times post transduction. Negative (mock transduced) and positive (reference vector) controls were included in each assay. Cells were harvested at day 10 and total DNA extracted using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) or MagNA Pure LC (Roche). The DNA concentration was analyzed by spectrophotometer and adjusted to 30 ng ml A stock of plasmid DNA containing the amplicon was used to prepare standards of known copy number to prepare a standard curve. DNA prepared from HEK293T cells containing a single EIAV (pONY8.4ZCG) vector copy, cloned by limiting dilution and verified by Southern blotting, was used as an internal reference standard. Samples were transferred to a 96-well optical plate and amplified using a TaqMan 7700 quantitative PCR machine using the cycling parameters: 50 1C for 2 min, 95 1C for 10 min, followed by 40 cycles of 95 1C for 15 s and 60 1C for 1 min. The plasmid standard dilution series was used to plot a regression curve of Ct plotted against copies of EIAV packaging signal. The predicted number of TU per millilitre of each sample was calculated from the regression equation and normalized to the pONY8.4ZCG reference standard. Titres were adjusted to account for the number of cells at the time of transduction and the dilution and volume of the vector applied.
Viral RNA titre assay Viral RNA was extracted and DNase I treated as previously described. 28 Negative (buffer) and positive (reference vector) controls were processed in parallel. A dilution series of an RNA standard of known copy number containing the EIAV packaging signal was used to prepare a standard curve. Analysis was carried out in duplicate. The PCR mix consisted of 1 Â One-step RT-PCR Master Mix containing Reverse Transcriptase and RNaseI Inhibitor (Applied Biosystems) and primers and probe as described above. Parallel control reactions Lentiviral vectors for factor VIII gene transfer PA Radcliffe et al were set up in which the reverse transcriptase was omitted in order to assess levels of DNA contamination.
Western blot analysis
Vector samples were pelleted by centrifugation and loaded onto a 10% polyacrylamide denaturing gel. Blots were probed with either anti-VSV-G-peroxidase (Roche, Cat. 1814133) or serum from a horse positive for EIAV (a kind gift from R Montelaro) followed by a peroxidase conjugated anti-horse secondary antibody (SigmaAldrich, St Louis, MO, USA, Cat. A-6917) and visualized with ECL Advance Western Blotting Detection Kit (GE Healthcare UK Ltd, Little Chalfont, UK).
Measurement of FVIII levels by COATEST
Transduced HepG2 cells were passaged on day 4 and 7 post transduction. On day 11 cells were harvested for DNA extraction and analysis of vector copy number as described for the integration titre assay. At the first passage a proportion of cells were maintained for analysis of FVIII production: 1 ml fresh media was added to each well (approximately 1 Â 10 6 cells per well) 5 days post transduction and culture supernatant collected after 24 h. Culture supernatants were filtered (0.2 mm) and stored at À80 1C prior to analysis. FVIII activity was measured using the COATEST VIII: C/4-821918 kit (Chromogenix, Lexington, MA, USA) in a modified 96-well plate format using reconstituted normal human plasma (Chromogenix) as a reference standard. Sample dilution was adjusted as appropriate to the assay sensitivity and range of the standard curve.
Statistical analysis
All values are expressed as means + (or ±) s.d., n ¼ 3, and are representative of experiments repeated at least once.
